Newsletter Subscription

Enter Name and Email

04 March 2014 - European Commission approves Orphan Medicinal Product designation for NLX-101

Neurolixis Inc., of which Adrian Newman-Tancredi, PhD, DSc, is co-founder and Chief Scientific Officer, announced that the European Commission approved its application for Orphan Medicinal Product Designation for NLX-101 in the treatment of Rett syndrome (see European Commission register). Rett syndrome is a rare genetic disorder that affects 1 female in about 10 000 and causes extensive and debilitating symptoms. NLX-101 targets the breathing difficulties that are commonly experienced by Rett syndrome patients. Orphan Medicinal Product designation provides a ten-year period of European Union marketing exclusivity as well as other benefits.

See the full press announcement here.

Adrian Newman-Tancredi has long-standing experience in neurobiology. For more information, Contact.